mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Company profile
Ticker
MRSN
Exchange
Website
CEO
Anna Protopapas
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MERSANA THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Mersana Securities Corp. ...
MRSN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
28 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
POS AM
Prospectus update (post-effective amendment)
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 24
8-K
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
S-8
Registration of securities for employees
12 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
Transcripts
MRSN
Earnings call transcript
2023 Q4
28 Feb 24
MRSN
Earnings call transcript
2023 Q3
7 Nov 23
MRSN
Earnings call transcript
2023 Q1
9 May 23
MRSN
Earnings call transcript
2022 Q4
28 Feb 23
MRSN
Earnings call transcript
2022 Q3
7 Nov 22
MRSN
Earnings call transcript
2022 Q2
9 Aug 22
MRSN
Earnings call transcript
2022 Q1
9 May 22
MRSN
Earnings call transcript
2021 Q4
28 Feb 22
MRSN
Earnings call transcript
2021 Q3
9 Nov 21
MRSN
Earnings call transcript
2021 Q2
6 Aug 21
Latest ownership filings
4/A
Ashish Mandelia
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G
SILVERARC CAPITAL MANAGEMENT, LLC
14 Feb 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G
BALYASNY ASSET MANAGEMENT L.P.
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
4
Anna Protopapas
17 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 186.76 mm | 186.76 mm | 186.76 mm | 186.76 mm | 186.76 mm | 186.76 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.21 mm | 20.41 mm | 15.36 mm | 15.68 mm |
Cash used (since last report) | n/a | n/a | 102.32 mm | 121.32 mm | 91.30 mm | 93.20 mm |
Cash remaining | n/a | n/a | 84.44 mm | 65.45 mm | 95.46 mm | 93.56 mm |
Runway (months of cash) | n/a | n/a | 4.9 | 3.2 | 6.2 | 6.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 134 |
Opened positions | 25 |
Closed positions | 52 |
Increased positions | 35 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 143.77 bn |
Total shares | 135.91 mm |
Total puts | 48.31 k |
Total calls | 1.06 mm |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
EcoR1 Capital | 19.36 mm | $24.59 bn |
VR Adviser | 11.33 mm | $14.39 bn |
Venrock Healthcare Capital Partners III | 9.68 mm | $12.19 mm |
Bain Capital Life Sciences Investors | 8.66 mm | $11.00 bn |
BLK Blackrock | 7.97 mm | $10.13 bn |
Vanguard | 6.19 mm | $7.86 bn |
BLVGF Bellevue | 5.22 mm | $6.63 bn |
Balyasny Asset Management | 5.04 mm | $6.40 bn |
Silverarc Capital Management | 5.00 mm | $6.35 bn |
BBBOF BB Biotech | 4.07 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jan 24 | Mohan Bala | Common Stock | Sell | Dispose S | No | Yes | 2.71 | 3,431 | 9.30 k | 14,052 |
16 Jan 24 | Brian DeSchuytner | Common Stock | Sell | Dispose S | No | Yes | 2.71 | 9,327 | 25.28 k | 54,511 |
16 Jan 24 | Carvajal Alejandra | Common Stock | Sell | Dispose S | No | Yes | 2.71 | 4,381 | 11.87 k | 27,403 |
16 Jan 24 | Timothy B Lowinger | Common Stock | Sell | Dispose S | No | Yes | 2.71 | 10,409 | 28.21 k | 199,329 |
15 Jan 24 | Huber Martin H. Jr. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 44,250 | 0.00 | 44,250 |
15 Jan 24 | Huber Martin H. Jr. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.02 | 199,125 | 601.36 k | 199,125 |
15 Jan 24 | Mohan Bala | RSU Common Stock | Grant | Acquire A | No | No | 0 | 58,333 | 0.00 | 58,333 |
15 Jan 24 | Mohan Bala | Stock Option Common Stock | Grant | Acquire A | No | No | 3.02 | 262,500 | 792.75 k | 262,500 |
15 Jan 24 | Brian DeSchuytner | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,958 | 0.00 | 63,838 |
15 Jan 24 | Brian DeSchuytner | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,250 | 0.00 | 59,880 |
News
JP Morgan Upgrades Mersana Therapeutics to Neutral, Announces $5 Price Target
19 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
15 Mar 24
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
29 Feb 24
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
29 Feb 24
Press releases
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
Mersana Therapeutics to Present at Upcoming Investor Conferences
27 Feb 24
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
21 Feb 24
Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference
1 Feb 24
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
5 Jan 24